<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126993</url>
  </required_header>
  <id_info>
    <org_study_id>E2019144</org_study_id>
    <nct_id>NCT04126993</nct_id>
  </id_info>
  <brief_title>Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma</brief_title>
  <official_title>Anti-PD-1 Antibody SHR-1210 (Camrelizumab) Combined With Apatinib Mesylate in the Treatment of Unresectable Sarcoma With Chemotherapy Failure: an Open, Non-randomized Phase II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the effectiveness of SHR-1210 (Camrelizumab) combined with apatinib in the&#xD;
      treatment of unresectable sarcoma patients with chemotherapy failure. The main observations&#xD;
      were progression-free survival (PFS) and progression-free control rate (PFR), followed by&#xD;
      objective response rate (ORR) (CR+PR), disease control rate (DCR) (CR+PR+SD), and overall&#xD;
      survival (OS).&#xD;
&#xD;
      To observe the safety of SHR-1210 (Camrelizumab) combined with apatinib in the treatment of&#xD;
      sarcoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Within 2 years</time_frame>
    <description>PFS is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR）</measure>
    <time_frame>Within 2 years</time_frame>
    <description>nvestigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1（RECIST1.1）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate (ORR)</measure>
    <time_frame>Within 2 years</time_frame>
    <description>ORR is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>Within 3 years</time_frame>
    <description>OS is defined as the length of time from random assignment to death or to last contact.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab+ Apatinib test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apatinib single drug control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab,</intervention_name>
    <description>Camrelizumab+ Apatinib test group: intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.</description>
    <arm_group_label>Camrelizumab+ Apatinib test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.</description>
    <arm_group_label>Apatinib single drug control group</arm_group_label>
    <arm_group_label>Camrelizumab+ Apatinib test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients voluntarily join the study, sign informed consent, and have good compliance；&#xD;
&#xD;
          -  Pathologically confirmed patients with unresectable sarcoma (except GIST), clinical&#xD;
             stage using the American Cancer Research Joint Committee (AJCC) TNM staging criteria.&#xD;
             At least 1 double-path measurable lesion according to CT or MR I;&#xD;
&#xD;
          -  At least one chemotherapy regimen (containing an anthracycline) was used to treat&#xD;
             patients with disease progression or intolerance according to the solid tumor efficacy&#xD;
             evaluation criteria (RECIST 1.1);&#xD;
&#xD;
          -  Clear cell sarcoma, alveolar soft tissue sarcoma can be directly into the group&#xD;
             without chemotherapy;&#xD;
&#xD;
          -  14~75 years old, PS score: 0~2; expected survival period is more than 3 months;&#xD;
&#xD;
          -  All acute toxic reactions caused by previous anti-tumor treatment or surgery are&#xD;
             relieved to 0-1 before screening (according to NCI CTCAE version 4.03) or to the level&#xD;
             specified by the enrollment/exclusion criteria (alopecia, etc. Except for toxicity&#xD;
             that does not pose a safety risk to the subject);&#xD;
&#xD;
          -  There are sufficient organ and bone marrow functions, defined as follows:&#xD;
&#xD;
               -  Blood routine (no blood transfusion within 14 days before treatment, no use of&#xD;
                  G-CSF, no use of drugs to correct), Neutrophil count (ANC) ≥ 1,500/mm3 (1.5 ×&#xD;
                  109/L); Platelet count (PLT) ≥ 100,000/mm3 (100 × 109/L); Hemoglobin (Hb) ≥ 9&#xD;
                  g/dL (90 g/L);&#xD;
&#xD;
               -  Blood chemistry, Serum creatinine (Cr) ≤ 1.5 × upper limit of normal (ULN) or&#xD;
                  creatinine clearance (Cockroft-Gault formula) ≥ 60 ml / min; Total bilirubin&#xD;
                  (TBIL) ≤ 1.5 × ULN; Aspartate aminotransferase (AST) or alanine aminotransferase&#xD;
                  (ALT) levels ≤ 2.5 × ULN, liver metastases should be ≤ 5 × ULN;&#xD;
&#xD;
               -  Coagulation, International normalized ratio (INR) ≤ 1.5, prothrombin time (PT)&#xD;
                  and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;&#xD;
&#xD;
               -  Urine routine, Urine protein &lt;2+; if urine protein ≥ 2+, 24-hour urine protein&#xD;
                  quantitation shows that the protein must be ≤ 1g;&#xD;
&#xD;
               -  Thyroid function, Thyroid stimulating hormone (TSH) ≤ ULN; if abnormalities&#xD;
                  should be considered T3 and T4 levels, T3 and T4 levels can be selected;&#xD;
&#xD;
          -  Female subjects of childbearing age must undergo a serum pregnancy test within 7 days&#xD;
             prior to treatment and the results are negative, and are willing to use a medically&#xD;
             recognized effective contraceptive measure during the study period and within 3 months&#xD;
             after the last administration of the study drug (eg: Intrauterine devices,&#xD;
             contraceptives or condoms; for male subjects whose partners are women of childbearing&#xD;
             age, surgical sterilization is required, or an effective method of contraception is&#xD;
             recommended during the study period and within 3 months after the last study&#xD;
             administration;&#xD;
&#xD;
          -  With my consent and signed informed consent, I am willing and able to follow planned&#xD;
             visits, research treatments, laboratory tests and other testing procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The following treatments were received within 4 weeks of treatment:&#xD;
&#xD;
               -  Radiotherapy, surgery, chemotherapy, immunization or molecular targeted therapy&#xD;
                  for tumors; Other clinical research drugs; Vaccination live attenuated vaccine;&#xD;
&#xD;
          -  Previously received treatment with PD-1/PD-L1/CTLA-4 antibody or VEGFR single&#xD;
             target/multi-target inhibitor;&#xD;
&#xD;
          -  Surgery and/or radiation therapy for soft tissue sarcomas is planned during the study&#xD;
             (regardless of &lt;5% of the bone marrow area);&#xD;
&#xD;
          -  Imaging diagnosis of central nervous system tumors;&#xD;
&#xD;
          -  Immune-suppressing drugs have been used within 14 days prior to initiation of&#xD;
             treatment, excluding nasal and inhaled corticosteroids or physiological doses of&#xD;
             systemic steroid hormones (That is, no more than 10 mg / day of prednisolone or&#xD;
             equivalent physiological dose of other corticosteroids);&#xD;
&#xD;
          -  There is any active autoimmune disease or a history of autoimmune disease (Including&#xD;
             but not limited to: Autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis,&#xD;
             hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism,&#xD;
             hypothyroidism; Subjects with vitiligo or asthma that have been completely relieved in&#xD;
             childhood and currently do not require medical intervention may be included, or a&#xD;
             history of allogeneic organ transplantation or a history of allogeneic hematopoietic&#xD;
             stem cell transplantation);&#xD;
&#xD;
          -  Severe infections (such as intravenous infusion of antibiotics, antifungal or&#xD;
             antiviral drugs) within 4 weeks prior to treatment, or unexplained fever &gt;38.5 °C&#xD;
             during screening/first administration;&#xD;
&#xD;
          -  High blood pressure, and excellent control without antihypertensive medication&#xD;
             (systolic blood pressure &gt;140 mmHg or diastolic blood pressure &gt;90 mmHg)&#xD;
&#xD;
          -  There are significant clinically significant bleeding symptoms or clear bleeding&#xD;
             tendency within 3 months before treatment, such as gastrointestinal bleeding,&#xD;
             hemorrhagic gastric ulcer, baseline fecal occult blood ++ and above, vasculitis, etc.&#xD;
             Or venous/venous thrombosis events occurring within 6 months prior to treatment, such&#xD;
             as cerebrovascular accidents (including transient ischemic attacks, cerebral&#xD;
             hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; or&#xD;
             require long-term anticoagulant therapy with warfarin or heparin, or long-term&#xD;
             antiplatelet therapy (aspirin ≥ 300 mg / day or clopidogrel ≥ 75 mg / day);&#xD;
&#xD;
          -  There were active heart disease in the 6 months before treatment, including myocardial&#xD;
             infarction, severe/unstable angina. Echocardiography left ventricular ejection&#xD;
             fraction &lt;50%, poorly controlled arrhythmia (including QTcF interval men &gt; 450 ms,&#xD;
             women &gt; 470 ms);&#xD;
&#xD;
          -  Any other malignant tumor was diagnosed within 3 years prior to treatment, except for&#xD;
             adequately treated basal cells or squamous cell skin cancer or cervical carcinoma in&#xD;
             situ;&#xD;
&#xD;
          -  It is known to be allergic to the study drug or any of its excipients; or to have a&#xD;
             severe allergic reaction to other monoclonal antibodies;&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection, active hepatitis B (HBV-positive and HBV&#xD;
             DNA ≥ 500 IU/ml), Hepatitis C (positive hepatitis C antibody and higher detection&#xD;
             limit of HCV-RNA than analytical methods);&#xD;
&#xD;
          -  At the discretion of the investigator, there are concomitant diseases (such as poorly&#xD;
             controlled hypertension, severe diabetes, neurological or psychiatric disorders, etc.)&#xD;
             that seriously compromise the safety of the subject, may confuse the findings, or&#xD;
             affect the subject's completion of the study. Any other situation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jilong Yang, M.D., Ph.D</last_name>
    <phone>+8618622221626</phone>
    <email>yangjilong@tjmuch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Hospital &amp; Institute</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jilong Yang, M.D., Ph.D.</last_name>
      <phone>+8618622221626</phone>
      <email>yangjilong@tjmuch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHR-1210</keyword>
  <keyword>Camrelizumab</keyword>
  <keyword>Apatinib</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Jilong Yang</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

